Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00687713
First received: May 29, 2008
Last updated: May 23, 2011
Last verified: May 2011

May 29, 2008
May 23, 2011
May 2008
May 2011   (final data collection date for primary outcome measure)
Abstinence [ Time Frame: Weeks 11 and 12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00687713 on ClinicalTrials.gov Archive Site
Overall reduction of use (sustained abstinence) [ Time Frame: 21 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Methamphetamine Dependence
  • Drug: Bupropion
    150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
  • Other: Placebo
    Placebo
  • Experimental: 1
    Intervention: Drug: Bupropion
  • Placebo Comparator: 2
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have a DSM-IV diagnosis of methamphetamine dependence as determined by MINI
  • Must have at least 1 amphetamine or methamphetamine positive urine specimen after the start of screening and before randomization or provide information to verify recent use if a positive urine sample can't be obtained
  • Must report using methamphetamine for 29 days or less during the 30 day period prior signing consent using the timeline follow-back method
  • Must be willing and able to comply with study procedures
  • Must be able to verbalize and understand consent forms and provide written informed consent
  • Must be seeking treatment for methamphetamine dependence

Exclusion Criteria:

  • Please contact study site for more information
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00687713
MDS Bupropion Meth 0001
Yes
Liza Gorgon, National Institute on Drug Abust (NIDA)
National Institute on Drug Abuse (NIDA)
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP